Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2026-01-14 00:42Group 1 - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Isavuconazole sulfate raw material [1][3] - The drug Isavuconazole sulfate is a triazole antifungal agent, which is a prodrug that converts to the active metabolite Isavuconazole in the body [4] - The company has invested approximately RMB 5.1287 million in the research and development of this drug [4] Group 2 - The approval indicates that the raw material meets the domestic drug registration requirements and can be sold in the domestic market [6] - The total procurement amount for Isavuconazole sulfate formulations in mainland China hospitals in 2024 is RMB 304.291 million [5] - The company has increased its stake in Shanghai Shanshi Group Financial Co., Ltd. from 30% to 40% through the acquisition of a 10% equity stake for approximately RMB 143 million [9][10]